ArticleThe Lancet. Global health2023
Quantitative estimates of preventable and treatable deaths from 36 cancers worldwide: a population-based study.
Article in The Lancet. Global health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
105 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Risk of Liver Cancer From Major Causes Compared to Smoking and Lung Cancer: A Systematic Review and Meta-Analysis.Journal of viral hepatitis · 2026Pooled it
- Utilization of cervical cancer screening and its associated factors among women living with HIV in East Africa: a systematic review and meta-analysis.BMC women's health · 2025Pooled it
- The hepatorenal protective effects of silymarin in cancer patients receiving chemotherapy: a randomized, placebo-controlled trial.BMC complementary medicine and therapies · 2024Trial
- Comprehensive Genomic Analysis of Normal and Cancer Cells Elucidates the Elevated Mutational Burden in Cancer.Cancer research · 2026Article
- Dual-Functional Self-Assembled Nanoparticles for Synergistic Photodynamic Therapy and Antimetastatic Treatment of Colorectal Cancer.Pharmaceutics · 2026Article
- Global inequalities in tracheal, bronchus, and lung cancer care quality from 1990 to 2021.iScience · 2026Article
- Disparities in the global cancer burden attributable to modifiable risk factors: a systematic analysis for the Global Burden of Disease Study 2021.Science China. Life sciences · 2026Article
- Cancer burden among adults aged 65 years and older in Asia, 1990-2023: a systematic analysis of the Global Burden of Disease Study 2023.npj aging · 2026Article
- Publication Characteristics and Reporting Quality of GBD-Derived Burden of Disease Studies: A Cross-Sectional Analysis of Lung Cancer.Journal of evidence-based medicine · 2026Article
- Understanding Barriers to Cancer Pain Management: Insights From Patients and Healthcare Professionals-A Systematic Review.Public health challenges · 2026Review
- A One Health Perspective on Cancer: A Narrative Review.Medical sciences (Basel, Switzerland) · 2026Review
- Understanding age and sex differentials in cancer incidence and mortality: An international population-based study.International journal of cancer · 2026Article
- Cancer: a looming public health crisis in Africa-a call to accelerate equitable access to medicines.The oncologist · 2026Article
- Inequalities in mammograms and cervical biopsies provision in the public and private sectors of the Brazilian healthcare system and the availability of gynecology and obstetrics specialists.Clinics (Sao Paulo, Brazil) · 2026Article
- Avoidable deaths through the primary prevention, early detection, and curative treatment of cancer worldwide: a population-based study.The Lancet. Global health · 2026Article
- HIF-1α siRNA Enhances the Efficacy of Erlotinib in Non-small Cell Lung Cancer: A Novel Strategy to Reverse Hypoxia-Induced Drug Resistance.Drugs in R&D · 2026Article
- Exosomal nanocarriers for targeted drug delivery in cancer therapy.Discover oncology · 2026Review
- The mechanistic role of Wilms tumor 1-associated protein in cancer pathogenesis, immunity, immunotherapy, and therapy resistance.Investigational new drugs · 2026Review
- Erectile Dysfunction and Its Impact on Health-Related Quality of Life in Prostate Cancer Patients: A Multicenter Cross-Sectional Study from Pakistan.Epidemiologia (Basel, Switzerland) · 2026Article
- Comparison and analysis of the immune landscape at the tumour invasion front in patients with pMMR/MSI-H and pMMR/MSS colorectal cancer.International journal of colorectal disease · 2026Article
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCancer is a leading cause of premature mortality globally. This study estimates premature deaths at ages 30-69 years and distinguishes these as deaths that are preventable (avertable through primary or secondary prevention) or treatable (avertable through curative treatment) in 185 countries worldwide.
methodsFor this population-based study, estimated cancer deaths by country, cancer, sex, and age groups were retrieved from the International Agency for Research on Cancer's GLOBOCAN 2020 database. Crude and age-adjusted cancer-specific years of life lost (YLLs) were calculated for 36 cancer types.
findingsOf the estimated all-ages cancer burden of 265·6 million YLLs, 182·8 million (68·8%) YLLs were due to premature deaths from cancer globally in 2020, with 124·3 million (68·0%) preventable and 58·5 million (32·0%) treatable. Countries with low, medium, or high human development index (HDI) levels all had greater proportions of YLLs at premature ages than very high HDI countries (68·9%, 77·0%, and 72·2% vs 57·7%, respectively). Lung cancer was the leading contributor to preventable premature YLLs in medium to very high HDI countries (17·4% of all cancers, or 29·7 million of 171·3 million YLLs), whereas cervical cancer led in low HDI countries (26·3% of all preventable cancers, or 1·83 million of 6·93 million YLLs). Colorectal and breast cancers were major treatable cancers across all four tiers of HDI (25·5% of all treatable cancers in combination, or 14·9 million of 58·5 million YLLs).
interpretationAlongside tailored programmes of early diagnosis and screening linked to timely and comprehensive treatment, greater investments in risk factor reduction and vaccination are needed to address premature cancer inequalities.
fundingErasmus Mundus Exchange Programme and the International Agency for Research on Cancer. TRANSLATIONS: For the German, French, Spanish and Chinese translations of the abstract see Supplementary Materials section.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.